ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年12月05日 09時00分
Source:
Eisai
エーザイ、第42回サンアントニオ乳がんシンポジウムにおいてエリブリン(ハラヴェン(R))に関する演題を発表
東京, 2019年12月05日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、2019年12月10日から14日まで米国テキサス州サンアントニオで開催される「第42回サンアントニオ乳がんシンポジウム(San Antonio Breast Cancer Symposium:SABCS2019)」において、当社が創製したエリブリンメシル酸塩(ハリコンドリン系微小管ダイナミクス阻害剤、製品名:「ハラヴェン(R)」、以下 エリブリン)に関する最新情報を発表することをお知らせします。
本学会では、進行性または転移性乳がん患者様を対象としたエリブリンの2つの臨床第III相試験の追加事後解析から全生存期間の予測因子としてエリブリン投与前時点におけるリンパ球数を評価した研究結果など、ポスター5演題が発表されます。
当社は、がん領域を重点領域の一つと位置づけており、がんの「治癒」に向けた革新的な新薬創出をめざしています。最先端のがん研究から革新的な創薬を行い、がん患者様とそのご家族、さらには医療従事者の多様なニーズの充足とベネフィット向上に、より一層貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201988.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025
Nov 26, 2024 17:55 JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 26, 2024 15:50 JST
Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues
Nov 26, 2024 10:51 JST
TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025
Nov 25, 2024 17:10 JST
Toyota Submits Progress Report on Recurrence Prevention Measures
Nov 25, 2024 15:43 JST
TOPVISION Launches Prospectus for the Listing Transfer from LEAP to the ACE Market
Nov 25, 2024 15:00 JST
MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant
Nov 25, 2024 14:18 JST
Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship
Nov 25, 2024 11:55 JST
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 18, 2024 23:30 JST
More Latest Release >>
Related Release
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
11/26/2024 3:50:00 PM JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
11/20/2024 11:51:00 AM JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
11/20/2024 10:24:00 AM JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/15/2024 2:31:00 PM JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
11/5/2024 11:35:00 AM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
11/1/2024 1:56:00 PM JST
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
10/31/2024 1:56:00 PM JST
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
10/31/2024 11:33:00 AM JST
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
10/17/2024 8:01:00 PM JST
More Press release >>